Latest Insider Transactions at Alpine Immune Sciences, Inc. (ALPN)
This section provides a real-time view of insider transactions for Alpine Immune Sciences, Inc. (ALPN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ALPINE IMMUNE SCIENCES, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ALPINE IMMUNE SCIENCES, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Jay Venkatesan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,650
+3.39%
|
$22,950
$3.62 P/Share
|
|
Mar 30
2021
|
Jay Venkatesan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,650
+3.51%
|
$30,600
$4.09 P/Share
|
|
Mar 05
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-3.57%
|
$120,000
$12.99 P/Share
|
|
Mar 04
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-3.45%
|
$130,000
$13.01 P/Share
|
|
Feb 02
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-3.33%
|
$110,000
$11.74 P/Share
|
|
Feb 01
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.62%
|
$120,000
$12.64 P/Share
|
|
Dec 31
2020
|
James Paul Rickey Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,258
-8.59%
|
$27,096
$12.6 P/Share
|
|
Dec 31
2020
|
Mitchell Gold Executive Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,123
-3.46%
|
$133,476
$12.6 P/Share
|
|
Dec 31
2020
|
Stanford L Peng Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,923
-13.87%
|
$47,076
$12.6 P/Share
|
|
Dec 28
2020
|
Peter A. Thompson Director |
SELL
Open market or private sale
|
Indirect |
600,000
-16.34%
|
$8,400,000
$14.25 P/Share
|
|
Dec 28
2020
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
600,000
-16.34%
|
$8,400,000
$14.25 P/Share
|
|
Dec 22
2020
|
Jay Venkatesan Director |
BUY
Other acquisition or disposition
|
Direct |
181,024
+47.17%
|
-
|
|
Dec 22
2020
|
Jay Venkatesan Director |
SELL
Other acquisition or disposition
|
Indirect |
993,801
-24.88%
|
-
|
|
Dec 22
2020
|
Alpine Immuno Sciences, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
993,801
-24.88%
|
-
|
|
Dec 22
2020
|
Mitchell Gold Executive Chairman and CEO |
BUY
Other acquisition or disposition
|
Direct |
260,528
+44.79%
|
-
|
|
Dec 22
2020
|
Mitchell Gold Executive Chairman and CEO |
SELL
Other acquisition or disposition
|
Indirect |
993,801
-24.88%
|
-
|
|
Nov 19
2020
|
Robert E Conway Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+28.57%
|
$80,000
$8.03 P/Share
|
|
Feb 08
2019
|
Tiger Management L.L.C. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
25,000
-15.36%
|
$125,000
$5.85 P/Share
|
|
Jan 18
2019
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
372,439
+9.21%
|
$1,862,195
$5.37 P/Share
|